New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
06:39 EDTCLVSClovis price target raised to $100 from $87 at Piper Jaffray
Piper Jaffray raised its price target for Clovis shares to $100 saying the company's clinical development programs are progressing well, with strong enrollment indicated for rociletinib and rucaparib trials. Piper reiterates an Overweight rating on the stock.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
16:03 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use